NetworkNewsBreaks – Vivos Therapeutics Inc. (NAS
Post# of 51
(Total Views: 327)
Posted On: 03/26/2021 6:11:13 PM
NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2020 Financial, Operational Results
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to discuss the new report. High on the list of significant achievements for the company was a full-year revenue increase of 15%; revenue for 2020 was $13.1 million compared to $11.4 million in 2019. Gross profit and margin was up for both the fourth quarter and fiscal year; the report noted that Vivos also completed a $21.6 million initial public offering in December 2020. Other highlights for the company included the commercial launch of AireO2, a new patient-management software technology, and VivoScore(TM), a comprehensive home sleep test. In addition, the company submitted an FDA 510(k) application for the Vivos mmRNA oral appliance(R). “Successfully introducing a disruptive technology like ours takes a passionate mission-driven team, sufficient capital resources and a little time to execute,” said Vivos chair and CEO Kirk Huntsman in the press release. “Last December, we took a huge step forward with the completion of our IPO, which provided the financial resources to execute our go-to-market strategy. Despite a global pandemic that closed dental offices across the U.S. and Canada for extended periods of time, our company still produced strong 2020 revenue results. . . . We remain fiercely committed to establishing revenue opportunities from complimentary technologies and services.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to discuss the new report. High on the list of significant achievements for the company was a full-year revenue increase of 15%; revenue for 2020 was $13.1 million compared to $11.4 million in 2019. Gross profit and margin was up for both the fourth quarter and fiscal year; the report noted that Vivos also completed a $21.6 million initial public offering in December 2020. Other highlights for the company included the commercial launch of AireO2, a new patient-management software technology, and VivoScore(TM), a comprehensive home sleep test. In addition, the company submitted an FDA 510(k) application for the Vivos mmRNA oral appliance(R). “Successfully introducing a disruptive technology like ours takes a passionate mission-driven team, sufficient capital resources and a little time to execute,” said Vivos chair and CEO Kirk Huntsman in the press release. “Last December, we took a huge step forward with the completion of our IPO, which provided the financial resources to execute our go-to-market strategy. Despite a global pandemic that closed dental offices across the U.S. and Canada for extended periods of time, our company still produced strong 2020 revenue results. . . . We remain fiercely committed to establishing revenue opportunities from complimentary technologies and services.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Vivos Therapeutics Inc. (VVOS) Stock Research Links
Scroll down for more posts ▼